ZYNE on NASDAQ

Zynerba Pharmaceuticals

American pharmaceutical preparations company based in Radnor, founded in 2014. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Jan 1, 2014Founded1

Compare with Incannex Healthcare Inc., Actinium Pharmaceuticals, Inc. or Citius Pharmaceuticals, Inc., or pick any stock.

  • TickerZYNE on NASDAQ1
  • IndustryPharmaceutical Preparations1
  • HeadquartersRadnor1
  • Websitezynerba.com
  • Legal formDelaware corporation1
  • Incorporated inDE4
  • Business address80 W. Lancaster Avenue, Suite 300, Devon, Pa 193334
  • Filer categoryNon-accelerated filer, Smaller reporting company4
  • LEI549300JLJ5VQU2CN60163
  • StatusActive3
  • LEI statusLapsed (not renewed)3
  • Registered addressC/O THE CORPORATION TRUST COMPANY, 19801 Wilmington, United States3
  • Registered withDivision of Corporations, Department of State, 42942303

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2018

-46974.2%Operating margin5
-46408.3%Net margin5
-69.3%Return on equity6
-$32.7MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2018

  • Research and development100¢$27.2M

Out of $86.0K in revenue.57 The company lost money this year.

Financial statements

Revenue75$86.0K in 2018+1086% since 2016
0$25.0K$50.0K$75.0K$100.0K2016: $7.2K$7.2K20162017: $0$020172018: $86.0K$86.0K2018
Operating income785-$40.4M in 2018+74% since 2016
-$60.0M-$40.0M-$20.0M02016: -$23.2M-$23.2M20162017: -$32.8M-$32.8M2017+41%2018: -$40.4M-$40.4M2018+23%
Net income785-$39.9M in 2018+71% since 2016
-$40.0M-$30.0M-$20.0M-$10.0M02016: -$23.4M-$23.4M20162017: -$32.0M-$32.0M2017+37%2018: -$39.9M-$39.9M2018+25%
Fiscal year201620172018
Revenue$7.2K7$07$86.0K5
Research and development$16.8M7$22.8M8$27.2M5
Operating expenses
Operating income-$23.2M7-$32.8M8-$40.4M5
Income before tax
Income tax-$27.5K7$07$07
Net income-$23.4M7-$32.0M8-$39.9M5
Earnings per share
Earnings per share (diluted)
Shares (weighted, basic)
Shares (weighted, diluted)

Compare Zynerba Pharmaceuticals with another company

Leadership

Who has led Zynerba Pharmaceuticals, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Armando Anido2022

Chair

  1. Armando Anido2015–2023

President

  1. Terri B. Sebree2015–2023

Chief financial officer

  1. Richard A. Baron2015
  2. James E. Fickenscher2016–2023
201520202025
Board members and other officers (9)

Former names

  • Zynerba Pharmeceuticals, Inc.Oct 9, 2014 to Jun 30, 20154

Timeline

  1. Jul 20, 2022New chief executive Armando Anido becomes CEO12
  2. Jan 1, 2014Founded Founded1

Filings

139 filings to the SEC since October 2021: 2 annual reports, 6 quarterly reports, 26 major events, 56 insider forms, 3 large holders, 46 other. The latest 20:

  1. Feb 8, 2024SC 13G/A EDGAR
  2. Oct 19, 202315-12G EDGAR
  3. Oct 11, 2023EFFECT EDGAR
  4. Oct 11, 20234 EDGAR
  5. Oct 11, 20234 EDGAR
  6. Oct 11, 20234 EDGAR
  7. Oct 11, 20234 EDGAR
  8. Oct 11, 20234 EDGAR
  9. Oct 11, 20234 EDGAR
  10. Oct 11, 20234 EDGAR
  11. Oct 11, 20234 EDGAR
  12. Oct 11, 20234 EDGAR
  13. Oct 11, 20234 EDGAR
  14. Oct 11, 20234 EDGAR
  15. Oct 11, 20234 EDGAR
  16. Oct 11, 2023POS AM EDGAR
  17. Oct 11, 2023S-8 POS EDGAR
  18. Oct 11, 2023S-8 POS EDGAR
  19. Oct 11, 2023S-8 POS EDGAR
  20. Oct 11, 2023S-8 POS EDGAR

The 139 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

26 open-market trades by officers, directors and large owners since October 2021: 0 buys and 26 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 13, 2023Sebree Terri BPresidentSale12,401$1.33$16.5KForm 4
Sep 13, 2023Rosenberger BrianVP, Commercial & Business Dev.Sale6,411$1.33$8.5KForm 4
Sep 13, 2023Fickenscher James EChief Financial OfficerSale8,998$1.33$12.0KForm 4
Sep 13, 2023Jones Kenneth TSee RemarksSale2,505$1.33$3.3KForm 4
Sep 13, 2023ANIDO ARMANDOChairman & Chief Exec. OfficerSale17,830$1.33$23.7KForm 4
Jun 14, 2023Stephenson PamelaDirectorSale115$0.35$40Form 4
Jun 14, 2023MOCH KENNETH IDirectorSale115$0.35$40Form 4
Jun 14, 2023KISNER DANIEL LDirectorSale115$0.35$40Form 4
Jun 14, 2023FEDERICI WILLIAM JDirectorSale115$0.35$40Form 4
Jun 14, 2023Butler John P.DirectorSale115$0.35$40Form 4
Jun 14, 2023COOPER WARREN DDirectorSale115$0.35$40Form 4
Feb 15, 2023Parker Albert PChief Legal OfficerSale3,173$0.54$1.7KForm 4
Jan 23, 2023Sebree Terri BPresidentSale24,661$0.60$14.8KForm 4
Jan 23, 2023Fickenscher James EChief Financial OfficerSale17,769$0.60$10.7KForm 4
Jan 23, 2023Rosenberger BrianVP, Commercial & Business Dev.Sale12,663$0.60$7.6KForm 4
Jan 23, 2023ANIDO ARMANDOChairman & Chief Exec. OfficerSale35,453$0.60$21.3KForm 4
Jul 19, 2022Sebree Terri BPresidentSale8,281$1.10$9.1KForm 4
Jul 19, 2022Rosenberger BrianVP, Commercial & Business Dev.Sale4,289$1.10$4.7KForm 4
Jul 19, 2022Fickenscher James EChief Financial OfficerSale6,013$1.10$6.6KForm 4
Jul 19, 2022ANIDO ARMANDOChairman & Chief Exec. OfficerSale11,899$1.10$13.1KForm 4

All 26 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27